|

Pembrolizumab (KEYTRUDA® ) Clinical Trials

15 actively recruiting trials across 12 locations

▲ +3 trials since May 2026

Also known as: KEYTRUDA®, Keytruda, Pembrolizumab

Pipeline

Phase 1: 2Phase 2: 3Phase 3: 1Phase 1/2: 6Phase 2/3: 3

Top Sponsors

  • Eikon Therapeutics3
  • VLP Therapeutics1
  • National Cancer Institute (NCI)1
  • Medicenna Therapeutics, Inc.1
  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's1

Indications

Other3 trials

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1/2
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
Phase 2
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
Phase 3

Birmingham, Alabama1 trial

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Site # 0137

Phase 2/3

Dothan, Alabama1 trial

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

XCancer Research Network/Dothan Hematology & Oncology

Phase 1/2

Chandler, Arizona1 trial

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Ironwood Cancer & Research Centers

Phase 2/3

Scottsdale, Arizona1 trial

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Honor Health Research Institute

Phase 1/2

San Diego, California1 trial

A Beta-only IL-2 ImmunoTherapY Study

Sharp Memorial Hospital

Phase 1/2

San Francisco, California1 trial

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

UCSF Helen Diller Family Comprehensive Cancer Center

Phase 1

Stanford, California1 trial

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

Stanford University

Phase 1

New Haven, Connecticut1 trial

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Yale

Phase 2

Bethesda, Maryland1 trial

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

National Institutes of Health Clinical Center

Phase 2

Morristown, New Jersey1 trial

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Morristown Medical Center

Phase 1/2

Mineola, New York1 trial

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

NYU Langone Hospital Long Island

Phase 2/3

New York, New York1 trial

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Tisch Cancer Institute (TCI), Icahn School of Medicine

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.